Merck & Co.'s Transitional Year Is Off To A Sluggish Start

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The company, in the midst of a leadership and structural transition, said the pandemic negatively impacted revenues by about $600m.

Turtle
Merck & Co. got off to a slow financial start • Source: Alamy

Merck & Co., Inc..'s first quarter earnings call on 29 April was the last for CEO Ken Frazier, who is passing the leadership reins to president Robert Davis on 30 June. The financial results weren't a strong way for Frazier to go out, as Merck & Co.'s financials were negatively impacted by the COVID-19 pandemic and even the company's crown jewel – Keytruda – posted slower growth.

With about 70% of the company's pharmaceutical portfolio made up of physician administered products, including vaccines, Merck & Co. said...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.